Longeveron’s (LGVN) Hold Rating Reaffirmed at Maxim Group

Longeveron (NASDAQ:LGVN)‘s stock had its “hold” rating reiterated by research analysts at Maxim Group in a note issued to investors on Monday,Benzinga reports.

Several other research firms have also recently issued reports on LGVN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a research note on Tuesday, April 21st. HC Wainwright dropped their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Finally, Wall Street Zen cut Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.50.

Longeveron Stock Performance

LGVN traded up $0.00 during midday trading on Monday, hitting $0.85. 475,661 shares of the company were exchanged, compared to its average volume of 3,969,999. The company’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $0.73. The firm has a market capitalization of $19.69 million, a price-to-earnings ratio of -0.66 and a beta of -0.31. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.03. Longeveron has a 1-year low of $0.48 and a 1-year high of $1.80.

Longeveron (NASDAQ:LGVN) last posted its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.20. Longeveron had a negative net margin of 1,893.58% and a negative return on equity of 199.79%. The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $0.11 million. As a group, sell-side analysts predict that Longeveron will post -0.7 earnings per share for the current year.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new position in Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent quarter. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.